Effect of intranasal arginine vasopressin on human headache

Yang, Jun; Lu, Lu; Wang, Hong-Chang; Zhan, Hong; Hai, Guangfan; Pan, Yan-Juan; Lv, Qiong-Qing; Wang, Daxin; Wu, Yuquan; Li, Ren-ren; Lei, Xue; Wang, Xinhua; Deng, Xiaoming; Liu, Xinfeng; Qian, Yanning; Deng, Zhi-Kuan; Zhang, Zhijian; Zhan, Xin-Huan; Zhou, Xinjian; Wang, Guoliang; Zhai, Jian-Xin; Wang, Jingcheng

doi:10.1016/j.peptides.2012.07.029

Cited by 24 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The noxious stimulation enhanced the PVN synthesis and secretion of AVP (Yang et al, 2006d), which was transferred to other nervous structures, such as PAG (Yang et al, 2007a), NRM (Yang et al, 2006b(Yang et al, , 2009c and CdN (Yang et al, 2006a) to regulate the pain process in rats. Our study also suggested that the brain AVP, which was delivered through the olfactory region, could treat human headache, depending on (1) AVP concentration in both plasma and CSF which increased significantly in headache patients, who related with the headache level; (2) there was a positive correlation between plasma and CSF AVP concentration in headache patients; and (3) intranasal AVP relieved the human headache in a dosedependent manner (Yang et al, 2012).…”

Section: Discussionmentioning

confidence: 55%

“…The law of intranasal AVP treatment of migraine was worked out in the multi-center clinical studies. The results showed that intranasal 400 ng AVP is effective and had a role in 96.4% of migraine patients including 75.0% complete response; 200 ng AVP is effective in 89.3% of migraine patients including 46.4% complete response; and 100 ng AVP is effective in 60.7% of migraine patients including 28.6% complete response (Yang et al, 2012).…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

The role of arginine vasopressin in electroacupuncture treatment of primary sciatica in human

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 97%

The role of arginine vasopressin in electroacupuncture treatment of primary sciatica in human

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…AVP when dosed at 100-400 ng to such headache patients resulted in partial or complete headache remission in 96% of patients (27 of 28). Relief was recorded 60-180 minutes after dosing, and headache patients had higher plasma and CSF levels of AVP (Yang et al, 2012), indicating a possible endogenous role for AVP in these headaches. Nonhematopoietic erythropoietin, which has been found to be neuroprotective in animal studies, was well tolerated in humans on intranasal dosing at a dose of 1.5-3.0 mg/day for 4 days (Santos-Morales et al, 2017).…”

Section: Other Drugsmentioning

confidence: 99%

“…Other peptides that have been administered to humans via the nose include arginine-vasopressin (AVP) for the treatment of tension headaches and migraine (Yang et al, 2012). AVP when dosed at 100-400 ng to such headache patients resulted in partial or complete headache remission in 96% of patients (27 of 28).…”

Section: Other Drugsmentioning

confidence: 99%

Nose-to-Brain Delivery

Wang¹,

Xiong²,

Tsang³

et al. 2019

J Pharmacol Exp Ther

168

View full text Add to dashboard Cite

The global prevalence of neurologic disorders is rising, and yet we are still unable to deliver most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier consists of a tight layer of endothelial cells surrounded by astrocyte foot processes, and these anatomic features constitute a significant barrier to drug transport from the blood to the brain. One way to bypass the blood brain barrier and thus treat diseases of the brain is to use the nasal route of administration and deposit drugs at the olfactory region of the nares, from where they travel to the brain via mechanisms that are still not clearly understood, with travel across nerve fibers and travel via a perivascular pathway both being hypothesized. The nose-to-brain route has been demonstrated repeatedly in preclinical models, with both solution and particulate formulations. The nose-to-brain route has also been demonstrated in human studies with solution and particle formulations. The entry of device manufacturers into the arena will enable the benefits of this delivery route to become translated into approved products. The key factors that determine the efficacy of delivery via this route include the following: delivery to the olfactory area of the nares as opposed to the respiratory region, a longer retention time at the nasal mucosal surface, penetration enhancement of the active through the nasal epithelia, and a reduction in drug metabolism in the nasal cavity. Indications where nose-to-brain products are likely to emerge first include the following: neurodegeneration, posttraumatic stress disorder, pain, and glioblastoma.

show abstract

“…Various rodent pain models have also revealed that exogenous OXT and AVP can alleviate pain‐related behaviour 7,9‐15 . Furthermore, clinical studies have reported that OXT and AVP are effective in alleviating pain in humans 16‐20 . Considering that OXT and AVP have been shown to exert analgesic effects in patients with back pain and other pain related to orthopedic disease, 18,20 they may also prove to be effective candidates for a novel conservative OA treatment option.…”

Section: Introductionmentioning

confidence: 99%

The neurohypophysial oxytocin and arginine vasopressin system is activated in a knee osteoarthritis rat model

Nishimura

Kawasaki

Suzuki

et al. 2020

J Neuroendocrinology

View full text Add to dashboard Cite

Osteoarthritis (OA) causes chronic joint pain and significantly impacts daily activities. Hence, developing novel treatment options for OA has become an increasingly important area of research. Recently, studies have reported that exogenous, as well as endogenous, hypothalamic‐neurohypophysial hormones, oxytocin (OXT) and arginine‐vasopressin (AVP), significantly contribute to nociception modulation. Moreover, the parvocellular OXT neurone (parvOXT) extends its projection to the superficial spinal dorsal horn, where it controls the transmission of nociceptive signals. Meanwhile, AVP produced in the magnocellular AVP neurone (magnAVP) is released into the systemic circulation where it contributes to pain management at peripheral sites. The parvocellular AVP neurone (parvAVP), as well as corticotrophin‐releasing hormone (CRH), suppresses inflammation via activation of the hypothalamic‐pituitary adrenal (HPA) axis. Previously, we confirmed that the OXT/AVP system is activated in rat models of pain. However, the roles of endogenous hypothalamic‐neurohypophysial hormones in OA have not yet been characterised. In the present study, we investigated whether the OXT/AVP system is activated in a knee OA rat model. Our results show that putative parvOXT is activated and the amount of OXT‐monomeric red fluorescent protein 1 positive granules in the ipsilateral superficial spinal dorsal horn increases in the knee OA rat. Furthermore, both magnAVP and parvAVP are activated, concurrent with HPA axis activation, predominantly modulated by AVP, and not CRH. The OXT/AVP system in OA rats was similar to that in systemic inflammation models, including adjuvant arthritis; however, magnocellular OXT neurones (magnOXT) were not activated in OA. Hence, localised chronic pain conditions, such as knee OA, activate the OXT/AVP system without impacting magnOXT.

show abstract

Effect of intranasal arginine vasopressin on human headache

Cited by 24 publications

References 27 publications

The role of arginine vasopressin in electroacupuncture treatment of primary sciatica in human

The role of arginine vasopressin in electroacupuncture treatment of primary sciatica in human

Nose-to-Brain Delivery

The neurohypophysial oxytocin and arginine vasopressin system is activated in a knee osteoarthritis rat model

Contact Info

Product

Resources

About